| Literature DB >> 18329762 |
Xiao Wang1, Huali Jin, Xiaogang Du, Chun Cai, Yang Yu, Gan Zhao, Baowei Su, Shan Huang, Yanxin Hu, Dongmei Luo, Ruiping She, Xinsong Luo, Xianfang Zeng, Xinyuan Yi, Bin Wang.
Abstract
Levamisole (LMS) as an adjuvant enhances cell-mediated immunity in DNA vaccination; we investigated the efficacy and liver immunopathology alleviation of a DNA vaccine, VR1012-SjGST-32, in a LMS formulation in the murine challenge model. Compared to controls, the VR1012-SjGST-32 plus LMS can reduce worm and egg burdens, as well as, immunopathological complications associated chronic inflammation significantly in liver, which were apparently associated with Th1-type response. Together, these results suggest that the LMS as a potential Schistosome DNA vaccine adjuvant can enhance both worm killing and disease prevention, which is possibly mediated through the induction of a strong Th1-dominant environment in immunized mice.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18329762 DOI： 10.1016/j.vaccine.2008.01.056
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641